References
Paracrine effects of adipose-derived stem cells in cutaneous wound healing in streptozotocin-induced diabetic rats
Abstract
Objective:
The purpose of this study was to explore the paracrine effects of adipose-derived stem cells (ASCs) on cutaneous wound healing in diabetic rats
Method:
The ASCs were isolated and identified by immunofluorescent staining. The ASCs-conditioned medium (ASCs-CM) was harvested. Cell counting kit (CCK)-8 assay, scratch experiments, western blot and quantitative polymerase chain reaction (qPCR) were performed to observe the effects of ASCs-CM on fibroblasts. A full-thickness skin wound diabetic rat model was prepared, using 34 male, Sprague Dawley rats. ASCs-CM or negative-control medium (N-CM) was injected around the wound surface. The existing wound area was measured on days 4, 8, 12 and 16 after the postoperative day, and the wound tissues were collected for immunohistochemical staining and qPCR quantitative study.
Results:
In this experiment, the isolated cells were characterised as ASCs. The results of CCK-8 assay, cell scratch test, western blot and qPCR showed ASCs-CM could significantly promote the proliferation, migration and differentiation of fibroblasts. Simultaneously, the healing rate of full-thickness skin wounds in diabetic rats was significantly higher in the ASCs-CM group than the N-CM group on days 4, 8, 12 and 16. Immunohistochemical staining and qPCR results showed that the expression of vascular endothelial growth factor (VEGF, days 4 and 8), α-smooth muscle actin (SMA) (days 4 and 16), transforming growth factor (TGF)-β1 (days 4, 8 and 12) were higher in the ASCs-CM group than that of the N-CM group (p<0.05).
Conclusion:
This experiment demonstrated that ASCs-CM may accelerate wound healing in diabetic rats by promoting the secretion of TGF-β1, VEGF and the proliferation, migration and differentiation of fibroblasts.
According to the International Diabetes Federation Diabetes Atlas of 2021, the number of adult patients with diabetes worldwide has reached 536.6 million.1 Diabetic foot ulcers (DFUs) are estimated to occur in 25% of all patients with diabetes, resulting in extensive emotional, functional and economic consequences for patients and an added burden on the healthcare system.2
The high glucose state caused by diabetes can impair wound healing, and the incidence rate of diabetic ulcers is >25%.3 The standard treatment of diabetic ulcers focuses on blood glucose control, offloading high pressure, surgical debridement of necrotic tissue, as well as antibiotic therapy for bacterial superinfection.4,5 However, in some cases, hard-to-heal diabetic ulcers are not responsive to these treatments and many patients with diabetic ulcers fail to adhere with these supportive and medical therapies.6
Register now to continue reading
Thank you for visiting Journal of Wound Care's World Union of Wound Healing Supplement and reading some of our peer-reviewed resources for healthcare professionals. To read more, please register today.